Abstract: The present invention relates to a novel approach for treating coronavirus infections, particularly infections caused by MERS-CoV, SARS-CoV and SARS-CoV-2 variants. Based on effectively targeting and cleaving single stranded RNA viruses, the present invention provides Cas13d guide RNAs, to guide the Cas13d protein to a target site in the genome of humanized Coronaviridae that is conserved between MERS-CoV, SARS-CoV and SARS-CoV-2. The disclosed invention further provides an AAV vector comprising such a Cas13d guide RNA expression cassette as well as a Cas13d for treating coronavirus infections, especially COVID-19 infections.

Abstract: The present application describes a method of producing embryonic stem cell (ESC)-like cells derived from adult mammalian testis. Furthermore, the application describes to a method of producing embryoid bodies from ESC-like cells as well as a method of producing a tissue and/or a differentiated cell from the ESC-like cell or the embryoid body. In addition, an ESC-like cell, an embryoid body and/or differentiated cell and/or tissue obtainable by said methods and pharmaceutical preparations containing the same are provided. Finally, the application describes to the use of these products for medical treatments and the preparation of pharmaceutical compositions for medical treatments.

Abstract: Muscle activity can be reversibly arrested by administering a reagent, such as 2,3-butanedione monoxime (BDM), which selectively blocks the interaction of the contractile proteins actin and myosin. Muscle such as the heart is contacted with the reagent to arrest activity and, after surgery or transplantation, the reagent is removed from the muscle to restore muscle activity.